Dyve Announces Poster Presentation at 2023 AACR Annual Meeting
Dyve Biosciences , Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.
- Dyve Biosciences , Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.
- Dyve will present pre-clinical data from its lead oncology drug candidate, DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors.
- “Dyve continues to advance research in areas where we believe our pH modulation program can achieve the biggest impact for patients and we look forward to sharing new pre-clinical data on our DYV800 program at this year’s AACR.
- , Chief Executive Officer, Dyve.